| [1] |
Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference[J]. Pediatr Neurol, 2013, 49(4): 255-265.
|
| [2] |
Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States[J]. Genet Med, 2007, 9(2): 88-100.
|
| [3] |
Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho[J]. Nature Cell Biology, 2000, 2(5): 281-287.
|
| [4] |
Wienecke R, König A, Declue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity[J]. J Biol Chem, 1995, 270(27): 16409-16414.
|
| [5] |
Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling[J]. Proc Natl Acad Sci USA, 2002, 99(21): 13571-13576.
|
| [6] |
Beaumont TL, Limbrick DD, Smyth MD. Advances in the management of subependymal giant cell astrocytoma[J]. Childs Nerv Syst, 2012, 28(7): 963-968.
|
| [7] |
Kotulska K, Borkowska J, Roszkowski M, et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients[J]. Pediatr Neurol, 2014, 50(4): 307-312.
|
| [8] |
Pajak L, Jin F, Xiao GH, et al. Sustained cardiomyocyte DNA synthesis in whole embryo cultures lacking the TSC2 gene product[J]. Am J Physiol, 1997, 273(3 Pt 2): H1619-H1627.
|
| [9] |
Au KS, Rodriguez JA, Finch JL, et al. Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients[J]. Am J Hum Genet, 1998, 62(2): 286-294.
|
| [10] |
Niida Y, Lawrence-Smith N, Banwell A, et al. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis[J]. Hum Mutat, 1999, 14(5): 412-422.
|
| [11] |
Hodges AK, Li S, Maynard J, et al. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin[J]. Hum Mol Genet, 2001, 10(25): 2899-2905.
|
| [12] |
Hallett L, Foster T, Liu Z, et al. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review[J]. Curr Med Res Opin, 2011, 27(8): 1571-1583.
|
| [13] |
Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex[J]. N Engl J Med, 2006, 355(13): 1345-1356.
|
| [14] |
Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis[J]. Lancet, 2008, 372(9639): 657-668.
|
| [15] |
Northrup H, Wheless JW, Bertin TK, et al. Variability of expression in tuberous sclerosis[J]. J Med Genet, 1993, 30(1): 41-43.
|
| [16] |
Yates JR, Maclean C, Higgins JN, et al. The tuberous sclerosis 2 000 study: presentation, initial assessments and implications for diagnosis and management[J]. Arch Dis Child, 2011, 96(11): 1020-1025.
|
| [17] |
Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex[J]. Neurology, 2004, 63(8): 1457-1461.
|
| [18] |
宋治海．结节性硬化症1例[J/CD]．中华妇幼临床医学杂志(电子版)，2014，10(3): 397-398.
|
| [19] |
Hinton RB, Prakash A, Romp RL, et al. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group[J]. J Am Heart Assoc, 2014, 3(6): e001493.
|
| [20] |
Roach ES, Dimario FJ, Kandt RS, et al. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association[J]. J Child Neurol, 1999, 14(6): 401-407.
|